 |
|
|
| |
Drug-Drug Interaction Potential of Glecaprevir/Pibrentasvir Based on Real-World Medication Use in Patients With
Chronic Hepati tis C Virus Infection: Data From the German Hepatitis C-Registry (DHC-R) and PAN-Cohort
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Johannes Vermehren1, Klaus HW Boeker2, Mark Bondin3, Stefan Mauss4, Anita Pathil5, Hartwig Klinker6, Thomas Lutz7, Fiona Marra8, Jan Hetti nger9, Hari Varun Kalluri3, Henning Kleine9, Peter Buggisch10
1Department of Gastroenterology and Hepatology, University Hospital Frankfurt, Frankfurt, Germany; 2Hepatologische Praxis, Hannover, Germany; 3AbbVie Inc., North Chicago, Illinois, United States; 4Center for HIV and Hepatogastroenterology, Duesseldorf, Germany; 5University Hospital Heidelberg,
Heidelberg, Germany; 6University Hospital Wurzburg, Wurzburg, Germany; 7Infekti ologikum, Frankfurt, Germany; 8University of Liverpool, Liverpool, United Kingdom; 9AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany; 10Institute for Interdisciplinary Medicine IFI, Hamburg, Germany
|
| |
|
|
|
|
|
